Day: December 10, 2020

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD...

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis

Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p<0.005 in each study) with ublituximab demonstrating...

error: Content is protected !!